Quality of life in hypertension: The SF-12 compared to the SF-36

Canadian Journal of Clinical Pharmacology

Volumn 11, Issue 2, 2004, Pages

  Côté, Isabelle ^a,b   Grégoire, Jean Pierre ^c   Moisan, Jocelyne ^c   Chabot, Isabelle ^a,d  

^a UNIVERSITÉ LAVAL   (Canada)

^b Innovus Inc   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Hypertension; Quality of life; SF 12; SF 36

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HEALTH PROGRAM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 12; SHORT FORM 36; VALIDITY; ADOLESCENT; HEALTH SURVEY; MIDDLE AGED; REPRODUCIBILITY;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 20544465338     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Organisation Mondiale de la Santé. Critères éthiques appliables à la promotion des médicaments. Genève: Organisation Mondiale de la Santé; 1998.
2. Testa MA and Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835-840.
3. Lawrence WF, Fryback DG, Martin PA, et al. Health status and hypertension: A population-based study. J Clin Epidemiol 1996; 49: 1239-1245.
4. Fletcher AE, Chester PC, Hawkins CM, et al. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens 1989; 3: 125-130.
5. Hill JF, Bulpitt CJ and Fletcher AE. Angiotensin converting enzyme inhibitors and quality of life: the European trial. J Hypertens Suppl 1985; 3: S91-94.
6. Stewart AL, Hays RD and Ware JE. The MOS short-form general health survey. Med Care 1988; 26: 724-738.
7. Côté I, Grégoire JP and Moisan J. Health-related quality of life measurement in hypertension. A review of randomised controlled drug trials. Pharmacoeconomics 2000; 18: 435-450.
8. McHorney CA, Ware JE, Jr., Lu JFR, et al. The MOS 36-items Short-form Health Survey (SF-36): III: Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-63.
9. Ware JE, Jr., Kosinski M and Keller SD. A 12-items short-form health survey. Med Care 1996; 34: 220-233.
10. Pickard AS, Johnson JA, Penn A, et al. Replicability of SF-36 summary scores by the SF-12 in stroke patients. Stroke 1999; 30: 1213-1217.
11. Côté I, Grégoire JP, Moisan J, et al. A pharmacy-based health promotion programme in hypertension: cost-benefit analysis. Pharmacoeconomics 2003; 21: 415-428.
12. Dauphinee S, Gauthier L, Gandek B, et al. Readying a US measure of health status, the SF-36, for use in Canada. Clin Invest Med 1997; 20: 224-238.
13. Ware J, Snow K, Kosinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, Mass: The Health Institute, New England Medical Center; 1993.
14. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-155.
15. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1171-1178.
16. Lim LL and Fisher JD. Use of the 12-item short-form (SF-12) Health Survey in an Australian heart and stroke population. Qual Life Res 1999; 8: 1-8.
17. Bulpitt CJ and Fletcher AE. The measurement of quality of life in hypertensive patients: a practical approach. Br J Clin Pharmacol 1990; 30: 353-364.